Journal
VACCINE
Volume 20, Issue 3-4, Pages 359-369Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0264-410X(01)00374-7
Keywords
Sm23; DNA vaccine; Schistosoma mansoni
Categories
Funding
- PHS HHS [5R01-A124557-11] Funding Source: Medline
Ask authors/readers for more resources
Schistosomes are helminth parasites infecting at least 200 million people worldwide. In this study. we evaluated the feasibility of using a nucleic acid vaccine to induce protective immune responses to the Schistosoma mansoni integral membrane protein Sm23. C57BL/6 mice were immunized by intramuscular injection in three separate vaccination trials. ELISA and Western Blot analyses indicated that mice immunized with a DNA plasmid construct encoding Sm23 (Sm23-pcDNA) generated specific IgG for Sm23. while sera from mice immunized with the control pcDNA plasmid did not. The vaccine elicited IgG(2a), and IgG(1) antibody isotypes. We also tested the adjuvant activity of IL-12 and IL-4 on humoral responses to Sm23. Co-immunization with plasmid encoding IL-12 did not affect the level of anti-Sm23 IgG(2a), but did reduce the IgG(1) level. In contrast, co-injection with a plasmid encoding IL-4 significantly reduced the level of anti-Sm23 IgG(2a), while the level of IgG(1) was largely unchanged. Importantly. the Sm23-pcDNA vaccine provided statistically significant levels of protection against challenge infection (21-44%. P < 0.001-0.02). Co-administration of plasmids encoding either IL-12 or IL-4 did not significantly enhance this protective effect. (C) 2001 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available